Browse the evidence

Increasing dietary fiber intake significantly reduces systolic and diastolic blood pressure in adults with hypertension, regardless of concurrent antihypertensive medication use.

If you have high blood pressure, increasing your daily fiber intake by about 6-12 grams (e.g., adding more beans, oats, or vegetables) can significantly lower your blood pressure. This benefit holds true even if you are already taking blood pressure medication, making it a powerful addition to your current treatment plan.

Resistance training interventions lasting 8 weeks or more significantly improve muscular strength, physical performance, and body composition in older adults (≥65 years) diagnosed with pre-sarcopenia, sarcopenia, pre-frailty, or frailty.

If you are 65 or older and experiencing signs of frailty or muscle loss, start a supervised resistance training program at least twice a week. Focus on progressive overload, meaning you gradually increase the weight or difficulty over time. Consistency is key, with benefits seen even after just 8 weeks, though longer programs (around 23 weeks on average in studies) yield more robust results. This approach helps build muscle, improve balance, and maintain independence.

Combined diet and physical activity interventions significantly decrease the risk of Type 2 Diabetes in high-risk populations (e.g., prediabetes, obesity, impaired fasting glucose).

If you are at high risk for Type 2 Diabetes (e.g., prediabetes, obesity), combine dietary changes with physical activity. Focus on reducing calories/carbohydrates and engaging in supervised aerobic or resistance exercise. This combined approach is highly effective at preventing the onset of Type 2 Diabetes.

Higher levels of leisure-time physical activity are consistently and positively associated with higher cardiorespiratory fitness (CRF) in adults.

To improve your cardiorespiratory fitness, prioritize your leisure-time physical activity. This doesn't necessarily mean joining a gym; it includes any recreational exercise you do. The evidence shows that doing more of this activity consistently leads to better fitness levels, which is a strong predictor of long-term health.

Adherence to healthy dietary patterns (e.g., Mediterranean, DASH) significantly reduces the risk of atherosclerotic cardiovascular disease (ASCVD) events and all-cause mortality, with effect sizes comparable to pharmacological interventions.

Focus on eating more plants (fruits, vegetables, whole grains, legumes, nuts) and fish, while cutting back on sugary drinks, refined grains, and processed meats. This pattern, whether called Mediterranean or DASH, is as effective for heart health as many prescription drugs.

Macronutrient composition (low-carb vs. low-fat) has no significant difference on weight loss outcomes when total caloric intake and adherence are controlled.

Don't obsess over whether you should be low-carb or low-fat. The most important factor is that you eat fewer calories than you burn. You can achieve this with almost any dietary pattern (Mediterranean, low-carb, low-fat) as long as you stick to it and maintain a calorie deficit.

Liraglutide (3.0 mg daily) is effective for weight loss but significantly less so than Semaglutide, with a mean weight loss of 6.4% compared to 15.8%.

Liraglutide (3.0 mg daily) is an FDA-approved option for weight loss, but it produces roughly half the weight loss of Semaglutide (6.4% vs 15.8%). It requires daily injections, which may be burdensome, and you must reach the 3.0 mg dose to see full effects. If you cannot tolerate Semaglutide, this is a viable alternative, but expect less dramatic results.

Sustained positive energy balance (energy intake exceeding energy expenditure) is the primary driver of obesity and weight gain.

To lose weight, you must consume fewer calories than you burn. While the quality of your diet (e.g., Mediterranean patterns, limiting sugary drinks) helps manage hunger and health, the fundamental requirement for weight loss is a sustained negative energy balance.

Certain anti-diabetic medications, specifically insulin, can increase body weight, creating a conflict in treating obesity and T2DM simultaneously.

If you are prescribed insulin for diabetes, be aware it can cause weight gain. Discuss weight-neutral or weight-loss promoting alternatives (like GLP-1 agonists or SGLT2 inhibitors, though not explicitly named here, implied by 'anti-obesity drugs') with your doctor if weight management is a priority.

Once-weekly semaglutide (2.4 mg) significantly improves heart failure symptoms, physical limitations, and exercise capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, independent of the magnitude of weight loss.

If you have heart failure with preserved ejection fraction, are obese, and have type 2 diabetes, once-weekly semaglutide (2.4 mg) can significantly reduce your heart failure symptoms and help you lose weight. This treatment works even if your weight loss isn't as dramatic as in people without diabetes, suggesting it helps your heart directly. It is administered as a weekly injection, starting at a low dose to minimize side effects, and titrated up over 16 weeks.

Higher circulating levels of long-chain omega-3 fatty acids (EPA, DPA, DHA) are associated with a 15-18% lower risk of all-cause mortality compared to the lowest levels.

To potentially lower your risk of premature death, aim for higher blood levels of long-chain omega-3s (EPA, DHA, DPA). This study suggests that individuals with lower baseline levels may benefit most from increasing these fatty acids, potentially through supplementation if dietary intake is insufficient, as biomarker levels are a stronger predictor of longevity than self-reported fish consumption.

Higher circulating levels of long-chain omega-3 fatty acids are associated with lower risk of death from cardiovascular disease, cancer, and other causes.

Maintaining higher blood levels of marine omega-3s (EPA, DHA, DPA) is associated with a reduced risk of dying from heart disease, cancer, and other causes. This suggests that optimizing omega-3 status may support overall longevity beyond just heart health.

Group-based education excluding patients on insulin therapy results in greater reductions in HbA1c compared to interventions including patients on insulin therapy.

If you are on insulin, group education still helps, but the HbA1c reduction might be smaller than for those not on insulin. This may be due to the complexity of balancing insulin with lifestyle changes.

Training to muscle failure is not required for maximizing muscular strength or hypertrophy gains compared to training non-failure, provided training volume is equated.

You do not need to train to absolute muscular failure on every set to build maximum strength or muscle size. As long as you are close to failure (e.g., 1-3 reps in reserve) and you match the total number of reps/sets (volume) between your failure and non-failure groups, your results will be statistically identical. Prioritize non-failure training to reduce joint stress and improve recovery, unless you are a highly trained individual where failure might offer a slight hypertrophy edge.

The proportion of T2D attributable to diet is inversely correlated with age, being highest in younger adults (83.5% for ages 20-25) and lowest in older adults (27.7% for ages 95+).

Start eating well early in life. The proportion of diabetes cases driven by diet is highest in young adults, meaning early dietary habits have a massive impact on lifetime risk.

Genetically elevated body mass index (BMI) causally increases the risk of 316 distinct clinical diagnoses across circulatory, metabolic, respiratory, and genitourinary systems, with risk burden increasing significantly as BMI categories rise.

Your body weight is not just a cosmetic issue; it is a causal driver for hundreds of health conditions, including heart failure, diabetes, and sleep apnea. The risk increases as your BMI rises. Managing your weight through diet and activity is one of the most effective ways to reduce your risk for these specific, serious diseases, regardless of your genetic background.

GLP-1 receptor agonists delay gastric emptying, which reduces postprandial lipid and carbohydrate surges and contributes to satiety.

GLP-1 medications slow down how fast food leaves your stomach. This helps you feel full longer and prevents sharp spikes in blood sugar after meals.

GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE), death, and stroke in patients with type 2 diabetes.

If you have type 2 diabetes, GLP-1 receptor agonists can significantly lower your risk of heart attacks, strokes, and death. This benefit is independent of weight loss and is supported by large-scale data involving over 60,000 patients.

High body weight (obesity) causes increased psychological distress and depressive symptoms, primarily through weight stigma and biological mechanisms like HPA-axis dysregulation and systemic inflammation.

If you have obesity, be aware that societal stigma and biological factors like inflammation can contribute to depression. Focus on mental health support and reducing stigma rather than self-blame. Healthcare providers should adopt weight-inclusive attitudes to improve patient wellbeing.

Endurance-based exercise training induces skeletal muscle mitochondrial biogenesis through a hormetic feedback loop triggered by acute disruptions in cellular energy and ionic homeostasis.

To build more mitochondria and improve endurance, you must challenge your body's energy balance. This happens through endurance exercise (like running or cycling) or high-intensity interval training (HIIT). The key is that the exercise must be intense enough to disrupt your muscle's normal energy state (depleting ATP/creatine phosphate and raising AMP/Calcium), which signals your cells to build more mitochondria over time. Consistency and progressive overload are necessary because your body adapts to the stress.

Higher body mass index (BMI) is a strong, linear, and likely causal risk factor for severe COVID-19 outcomes, including hospitalization and death, with risk increasing by approximately 5-10% per kg/m² increase in BMI.

Maintaining a healthy weight is one of the most effective ways to reduce the risk of severe illness from COVID-19. The risk of hospitalization and death increases linearly with BMI. While weight loss is challenging, even modest reductions in weight (e.g., through bariatric surgery or lifestyle changes) have been associated with significantly lower risks of severe outcomes. Public health efforts should prioritize obesity prevention and management as a key strategy to mitigate the impact of the pandemic.

GLP-1 receptor agonists (GLP-1RAs) promote sustained weight loss in adults with obesity or type 2 diabetes primarily by increasing energy expenditure and reducing food intake via central nervous system satiety signaling, independent of glycaemic control.

If you have obesity or Type 2 Diabetes, GLP-1 medications like semaglutide or liraglutide are proven to help you lose significant weight (around 15% in trials) by reducing hunger and increasing energy burn. They are taken as a weekly or daily injection, often alongside diet and exercise changes. These are not quick fixes but chronic treatments that mimic a natural gut hormone to help regulate your body's weight set-point.

Once-weekly subcutaneous semaglutide (2.4 mg) significantly alters the circulating proteome in individuals with obesity, downregulating proteins associated with cardiovascular disease risk and inflammatory pathways beyond what is explained by weight loss and glycemic control alone.

If you have obesity and are considering semaglutide, know that it does more than just help you lose weight. It actively changes your blood proteins to lower your risk of heart disease and inflammation, even independent of the weight you lose. This makes it a valuable tool for cardiovascular protection in high-risk individuals, not just a weight-loss aid. The benefits are supported by large, rigorous clinical trials.

Tirzepatide 15mg is associated with a higher rate of adverse events compared to other GLP-1RAs, although not significantly different from placebo in some metrics, it ranks highest in SUCRA for adverse events.

Tirzepatide 15mg is highly effective but comes with a higher risk of side effects like nausea and diarrhea compared to other GLP-1s. Patients should be prepared for this and work with their doctor on dose titration to manage it.